To the Editor: With the article by Tang et al., 1 recently published in Kidney International, we anticipate that the lamivudine-resistant mutation and hepatitis flares will occur in their patients with hepatitis B virus-associated membranous nephropathy under further long-term lamivudine treatment. Although, hepatitis B virus variants with mutations at the YMDD motif of DNA polymerase have not been observed in their cohort, the proportion of patients with a documented lamivudine-resistant mutation increased from 23% in year 1 to 65% in year 5 was reported by Chayama et al. 2 and Lok et al. 3 In Tang et al.'s study, there were one (8.3%), three (25%), seven (58.3%), and one (8.3%) of 12 control patients with hepatitis B virus-associated membranous nephropathy did not receive lamivudine treatment went into partial remission, complete remission, no remission, and end-stage renal disease at 12 months, respectively. There was no patient with remission at 12 months went to end-stage renal disease by 3 years of follow-up. It implicated that the renal function would be conserved when patient's proteinuria declined into remission status. Therefore, long-term lamivudine treatment for patients with hepatitis B virus-associated membranous nephropathy after initial remission suggested by Tang et al. 1 may not be reasonable. Although the optimal duration of treatment and the criteria for stopping treatment have not been established, maintenance of lamivudine therapy for 4-6 months following chemotherapy was suggested. 4 We would like to reinforce the point that one of three (33.3%) patients with hepatitis B virus-associated membranous nephropathy would go to remission status at 12 months under supportive treatment in Tang et al.'s study. 1 Therefore, long-term lamivudine treatment should only be focused on patients with no remission instead of the patients with remission at 12 months.
